stocknshares / iStockphoto.com
Companies that sell their inventions to third parties under confidential agreements may still end up invalidating their own patents based on the “on-sale” provision, the US Supreme Court said today.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at firstname.lastname@example.org
SCOTUS, US, AIA, patent invalidation, Helsinn Healthcare, Teva, generic version, proprietary information, confidential sales